Duloxetine

Drug Profile

Duloxetine

Alternative Names: Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Shiga University of Medical Science; Shionogi
  • Class Antidepressants; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Depressive disorders; Diabetic neuropathies; Fibromyalgia; Generalised anxiety disorder; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Stress incontinence
  • Phase II/III Chronic fatigue syndrome

Most Recent Events

  • 01 Jul 2017 Shiga University of Medical Science, in collaboration with Shionogi, terminates phase II/III trial in Major depressive disorder (In adolescents) in Japan (E-DAD/UMIN000016192)
  • 19 Dec 2016 Launched for Musculoskeletal pain (associated with osteoarthritis) in Japan (PO)
  • 19 Dec 2016 Registered for Musculoskeletal pain (associated with osteoarthritis) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top